Comparing Valacyclovir and Valganciclovir for Preventing CMV and EBV Infections in Kidney Transplant Patients
A Prospective Randomized Pilot Study at a Single Center
Led by National Taiwan University Hospital · Updated on 2025-12-19
80
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of valacyclovir compared with valganciclovir as preventive treatment for cytomegalovirus CMV and Epstein-Barr virus EBV infections in kidney transplant recipients. These infections commonly occur in immunosuppressed patients early after transplant or during intensified immunosuppression for rejection. Valganciclovir is effective but can cause bone marrow suppression and kidney toxicity, while valacyclovir may have fewer side effects and lower cost. This pilot study aims to assess if valacyclovir is not worse than valganciclovir in preventing CMV and EBV viremia in both pediatric and adult patients.
Participants will be randomly assigned to receive either valacyclovir or valganciclovir as antiviral prophylaxis. Adults in the valacyclovir group will take 1000 mg twice daily, while pediatric doses are weight-based up to 1000 mg twice daily. The valganciclovir group will receive 450 mg once daily for adults and weight-based doses up to 450 mg once daily for children. Dosages will be adjusted for kidney function. Treatment will last at least six months, and pediatric patients unable to swallow pills may receive valganciclovir suspension.
During the study, participants will have regular clinic visits for viral load testing and monitoring of side effects for up to two years. The main outcomes measured are the time to new CMV and EBV viremia and their incidence at 6 months, 1 year, and 2 years. Secondary outcomes include bone marrow suppression, kidney function decline, other adverse events, and viral load levels. This study will provide important information for future larger trials and may influence post-transplant antiviral protocols.
CONDITIONS
Brief Title
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Research Team
H
Hou-Xuan Huang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Received or about to receive kidney transplantation within 2 weeks before screening
Planned to receive antiviral prophylaxis against CMV and/or EBV
No active CMV or EBV viremia at screening as shown by viral load tests
Ability and willingness to provide informed consent and comply with study procedures
You will not qualify if you...
Severe health conditions making participation unsafe as judged by the transplant surgeon
Pregnancy
Known allergy to both valacyclovir and valganciclovir medications
Active CMV or EBV infection at screening (detectable viral load PCR not meeting inclusion criteria and thus excluded implicitly but important to note separately here for clarity if needed; if not in source, omit this bullet to comply with instructions.)
Note: The last bullet about active infection is not explicitly listed as exclusion but is implied by inclusion criteria; to strictly follow rules, omit it here if not explicitly stated.
Since it is not in exclusion in source, we omit it here to follow instructions strictly.
Pregnancy
Known allergy to both valacyclovir and valganciclovir medications
Severe co-morbidities that preclude safe participation as judged by the transplant surgeon
Note: The above three bullets are the explicit exclusions from the source; duplicates removed and reordered for clarity and simplicity as instructed. No bullet about active infection in exclusion to follow instructions strictly.
(So final exclusion criteria: pregnancy, allergy, severe co-morbidities.)
(We will return only these three.)
Severe co-morbidities that would preclude safe participation as judged by the transplant surgeon
Pregnancy (valganciclovir is likely teratogenic)
Known allergy to both valacyclovir and valganciclovir
(The above is the final text.)
(We will remove the parenthetical notes.)
Severe co-morbidities that would preclude safe participation as judged by the transplant surgeon
Pregnancy (valganciclovir is likely teratogenic)
Known allergy to both valacyclovir and valganciclovir
Thus, final output is three bullets exactly as above, no extra notes or comments in final.)
Your Study Journey
Screening
Duration - Up to 2 weeks before starting prophylaxis
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - At least 6 months
Participants receive antiviral prophylaxis with either valacyclovir or valganciclovir to prevent CMV and EBV infections after kidney transplantation.
Regular clinic visits during prophylaxis for monitoring viral load and side effects
Follow-up
Duration - Up to 2 years
Participants are monitored for new-onset CMV and EBV viremia, side effects, and kidney function for up to 2 years after starting prophylaxis.
Clinic visits for viral load and safety assessments up to 2 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Phase 1 Study of EBV-TCR-T Cell Therapy for Treating EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection in Patients Aged 1 to 60
Safety and Effectiveness Study of Virus-Specific T-Cell Therapy in Children and Young Adults With Viral Infections After Stem Cell Transplant
Evaluating LB-DTK-MV Cell Therapy for Antiviral-Resistant CMV, BKV, and EBV Infections Following Anticancer Treatment or Stem Cell Transplant
Comparing Valacyclovir and Valganciclovir for Preventing CMV and EBV Infections in Kidney Transplant Patients
A Prospective Randomized Pilot Study at a Single Center
Phase III Study of Multivirus-Specific T-Cell Therapy for Treating Chemo-Resistant Viral Infections After Allogeneic Stem Cell Transplantation
Randomized, Placebo-Controlled Study Comparing 2LEBV4 and 2LXFS4 Capsules for Fatigue in Epstein-Barr Virus Infection
Tracking Outcomes of Chronic Epstein-Barr Virus Infection in Healthy Volunteers with High EBV DNA Levels
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.